Cargando…

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer

Metastatic breast cancer (MBC) is an extremely recalcitrant disease capable of bypassing current targeted therapies via engagement of several growth promoting pathways. SH2 containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase known to facilitate growth and survival signaling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hao, Libring, Sarah, Ruddraraju, Kasi Viswanatharaju, Miao, Jinmin, Solorio, Luis, Zhang, Zhong-Yin, Wendt, Michael K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714690/ https://www.ncbi.nlm.nih.gov/pubmed/33033382 http://dx.doi.org/10.1038/s41388-020-01488-5

Ejemplares similares

Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
por: Chen, Hao, et al.
Publicado: (2022)

Therapeutic Targeting of Protein Tyrosine Phosphatases from Mycobacterium tuberculosis
por: Ruddraraju, Kasi Viswanatharaju, et al.
Publicado: (2020)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2022)

Crystal structure of 5-{4′-[(2-{2-[2-(2-ammonioethoxy)ethoxy]ethoxy}ethyl)carbamoyl]-4-methoxy-[1,1′-biphenyl]-3-yl}-3-oxo-1,2,5-thiadiazolidin-2-ide 1,1-dioxide: a potential inhibitor of the enzyme protein tyrosine phosphatase 1B (PTP1B)
por: Ruddraraju, Kasi Viswanatharaju, et al.
Publicado: (2015)

Crystal structure of methyl (S)-2-{(R)-4-[(tert-butoxycarbonyl)amino]-3-oxo-1,2-thiazolidin-2-yl}-3-methylbutanoate: a chemical model for oxidized protein tyrosine phosphatase 1B (PTP1B)
por: Ruddraraju, Kasi Viswanatharaju, et al.
Publicado: (2015)

4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
por: Libring, Sarah, et al.
Publicado: (2020)

Crystal structure of a nucleoside model for the interstrand cross-link formed by the reaction of 2′-deoxyguanosine and an abasic site in duplex DNA
por: Catalano, Michael J., et al.
Publicado: (2016)

Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche
por: Shinde, Aparna, et al.
Publicado: (2020)

The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites
por: Libring, Sarah, et al.
Publicado: (2020)

SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016)

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
por: Abdullah, Ammara, et al.
Publicado: (2020)

Correction: Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
por: Abdullah, Ammara, et al.
Publicado: (2023)

In Vitro Magnetic Techniques for Investigating Cancer Progression
por: Libring, Sarah, et al.
Publicado: (2021)

Fibronectin-Expressing Mesenchymal Tumor Cells Promote Breast Cancer Metastasis
por: Jun, Brian H., et al.
Publicado: (2020)

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
por: Miao, Jinmin, et al.
Publicado: (2023)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
por: Zeng, Li-Fan, et al.
Publicado: (2014)

Strategies to overcome drug resistance using SHP2 inhibitors
por: Liu, Meng, et al.
Publicado: (2021)

A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
por: Song, Yihui, et al.
Publicado: (2021)

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
por: Amante, Romain J., et al.
Publicado: (2023)

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
por: Cruz-Duarte, Raquel, et al.
Publicado: (2022)

SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer
por: Zhang, Lei, et al.
Publicado: (2020)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
por: Jopling, Chris, et al.
Publicado: (2007)

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
por: Bunda, Severa, et al.
Publicado: (2015)

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
por: Pádua, Ricardo A. P., et al.
Publicado: (2018)

Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma
por: Li, Ye, et al.
Publicado: (2021)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
por: Pudelko, Linda, et al.
Publicado: (2020)

Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma
por: Hu, Zhongqian, et al.
Publicado: (2017)

Functions of Shp2 in cancer
por: Zhang, Jie, et al.
Publicado: (2015)

Sidestepping SHP2 inhibition
por: Popescu, Bogdan, et al.
Publicado: (2023)

Self-assembled multifunctional nanotheranostics against circulating tumor clusters in metastatic breast cancer
por: Dhandapani, Ramya, et al.
Publicado: (2023)

Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xu, Xiaozheng, et al.
Publicado: (2021)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
por: Taylor, Julia, et al.
Publicado: (2023)

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
por: Gebregiworgis, Teklab, et al.
Publicado: (2021)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer
por: Ma, Weike, et al.
Publicado: (2023)

Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_prqiuju0qvujdk51ktgv2211m1